FDA-Approved Ovarian Cancer Treatments
Generic Brand Strength Form Usual Dose
Alkylating agent
altretamine Hexalen 50mg caps 260mg/m² daily in four divided doses for either 14 or 21 consecutive days in a 28-day cycle
carboplatin 10mg/
soln for IV infusion Advanced ovarian cancer (previously untreated): 300mg/m² on Day 1 every 4wks for 6 cycles
Recurrent ovarian cancer: 360mg/m² on Day 1 every 4wks
cisplatin 1mg/mL soln for IV infusion after dilution 75–100mg/m² IV per cycle once every 3–4wks on Day 1
50mg/vial pwd for IV infusion after reconstitution and dilution
25mg, 50mg tabs 1–5mg/kg/day
500mg, 1g, 2g pwd for inj after reconsti
40–50mg/kg in divided doses over 2–5 days or 10–15mg/kg every 7–10 days or 3–5mg/kg twice weekly
melphalan Alkeran 2mg scored tabs 0.2mg/kg/day for 5 days; repeat every 4–5wks
thiotepa 15mg pwd for IV, intravesical, or intracavitary admini
stration after reconsti
0.3–0.4mg/kg IV once every 1–4wks
Antibiotics (cytotoxic)
doxorubicin 10mg, 20mg, 50mg pwd for IV inj after reconsti
Monotherapy: 60–75mg/m² every 21 days
Combination therapy: 40–60mg/m² every 21 to 28 days
2mg/mL soln for IV inj
doxorubicin (liposomal) Doxil 2mg/mL dispersion for IV infusion after dilution 50mg/m² once every 4wks
gemcitabine Gemzar 200mg, 1g pwd for IV infusion after reconsti
1000mg/m² on Days 1 and 8 of each 21-day cycle; give with carboplatin AUC 4 administered on Day 1 after gemcitabine
Infugem 1200mg/120mL, 1300mg/130mL, 1400mg/140mL, 1500mg/150mL, 1600mg/160mL, 1700mg/170mL, 1800mg/180mL, 1900mg/190mL, 2000mg/200mL, 2200mg/220mL soln for IV infusion
Antimicrotubule agents
paclitaxel Taxol 6mg/mL soln for IV admini
stration after dilution
Previously untreated ovarian cancer: 175mg/m² over 3hrs or 135mg/m² over 24hrs; repeat every 3wks
Previously treated ovarian cancer: 135mg/m² or 175mg/m² over 3hrs every 3wks
niraparib Zejula 100mg caps 300mg once daily until disease progression or unacceptable toxicity
olaparib Lynparza* 50mg caps 400mg twice daily until disease progression or unacceptable toxicity; max 800mg daily
100mg, 150mg tabs 300mg twice daily until disease progression or unacceptable toxicity; max 600mg daily. Maintenance of advanced ovarian cancer: continue until disease progression, unacceptable toxicity, or completion of 2yrs of treatment. Discontinue if complete response at 2yrs; may treat beyond 2yrs in those with evidence of disease if provider can derive further benefit from continuous treatment
rucaparib Rubraca* 200mg, 250mg, 300mg tabs 600mg twice daily until disease progression or unacceptable toxicity
Topoisomerase inhibitor
topotecan Hycamtin 4mg pwd for IV infusion after reconsti
tution and dilution
1.5mg/m² daily for 5 consecutive days starting on Day 1 of a 21-day cycle

*For patients with deleterious BRCA-mutated (as detected by an FDA-approved test) advanced ovarian cancer.

Not an inclusive list of medications and/or doses. Please see drug monograph at www.eMPR.com and/or contact company for full drug labeling.

(Rev. 1/2020)

This article originally appeared on MPR